Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-label placebo (non-deceptive and non-concealed administration) is superior to a no-treatment control with matched patient-provider interactions in the treatment of irritable bowel syndrome (IBS). METHODS: Two-group, randomized, controlled three week trial (August 2009-April 2010) conducted at a single academic center, involving 80 primarily female (70%) patients, mean age 47 ± 18 with IBS diagnosed by Rome III criteria and with a score ≥ 150 on the IBS Symptom Severity Scale (IBS-SSS). Patients were randomized to either open-label placebo pills presented as "placebo pills made of an inert substance, like sugar pills, that have been shown in clinical studies to produce significant improvement in IBS symptoms through mind-body self-healing processes" or no-treatment controls with the same quality of interaction with providers. The primary outcome was IBS Global Improvement Scale (IBS-GIS). Secondary measures were IBS Symptom Severity Scale (IBS-SSS), IBS Adequate Relief (IBS-AR) and IBS Quality of Life (IBS-QoL). FINDINGS: Open-label placebo produced significantly higher mean (±SD) global improvement scores (IBS-GIS) at both 11-day midpoint (5.2 ± 1.0 vs. 4.0 ± 1.1, p<.001) and at 21-day endpoint (5.0 ± 1.5 vs. 3.9 ± 1.3, p = .002). Significant results were also observed at both time points for reduced symptom severity (IBS-SSS, p = .008 and p = .03) and adequate relief (IBS-AR, p = .02 and p = .03); and a trend favoring open-label placebo was observed for quality of life (IBS-QoL) at the 21-day endpoint (p = .08). CONCLUSION: Placebos administered without deception may be an effective treatment for IBS. Further research is warranted in IBS, and perhaps other conditions, to elucidate whether physicians can benefit patients using placebos consistent with informed consent. TRIAL REGISTRATION: ClinicalTrials.gov NCT01010191.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The number-needed-to-treat was 11 which should be compared with 4 for ‘placebo without deception,259 7 for alosetron,260 8 for linaclotide261 and 14 for tegaserod.262”
From Intestinal microbiota in functional bowel disorders: a Rome foundation report (2013) · cites this paper as [259]
The cited source says what the claim attributes to it.
In the citing paper
“Several trials of psychological treatments for IBS have failed to show differential effects on symptoms when using attention control conditions [32,62-64], and a recent study showed that IBS patients even respond to open-label placebo [65].”
The cited source says what the claim attributes to it.
In the citing paper
“Kaptchuk and colleagues showed that an open label inactive placebo pill produced better outcomes in IBS patients compared to no treatment13.”
From Is ginger effective for the treatment of irritable bowel syndrome? A double blind randomized controlled pilot trial (2014) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Discovery of Grounded Theory; Strategies for Qualitative Research
Glaser, B. G., Strauss, A. L., & Strutzel, E. (1968) · Nursing Research · doi:10.1097/00006199-196807000-00014 · Cited by 39,449
Pharmacological interventions for somatoform disorders in adults
Kleinstäuber, M., Witthöft, M., Steffanowski, A., van Marwijk, H., Hiller, W., & Lambert, M. J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010628.pub2 · Cited by 11,335
Cohen, J. (1992) · Psychological Bulletin · doi:10.1037//0033-2909.112.1.155 · Cited by 8,771
Collecting and Interpreting Qualitative Materials
Denzin, N. K., & Lincoln, Y. S. (2012) · Cited by 6,094
Longstreth, G. F., Thompson, W. G., Chey, W. D., Houghton, L. A., Mearin, F., & Spiller, R. C. (2006) · Gastroenterology · doi:10.1053/j.gastro.2005.11.061 · Cited by 4,856
Functional bowel disorders and functional abdominal pain
Thompson, W. G., Longstreth, G. F., Drossman, D. A., Heaton, K. W., Irvine, E. J., & Müller-Lissner, S. A. (1999) · Gut · doi:10.1136/gut.45.2008.ii43 · Cited by 2,440 · cited 1×
“Participants were adults ($18 years old) meeting the Rome III criteria for IBS [17] with a score of $150 on the IBS Symptom Severity Scale (IBS-SSS).”
MethodFRANCIS, C. Y., MORRIS, J., & WHORWELL, P. J. (1997) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.1997.142318000.x · Cited by 1,708 · cited 3×
“[18] The open-label group improved by 92 points on this measure; in addition, the improvement shown by the openlabel placebo group exceeded that shown by the no-treatment group by 46 points.”
MethodInfluentialIs the Placebo Powerless?: An Analysis of Clinical Trials Comparing Placebo with No Treatment
Hróbjartsson, A., & Gøtzsche, P. C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105243442106 · Cited by 1,503
AGA technical review on irritable bowel syndrome.
Drossman, D. A., Camilleri, M., Mayer, E. A., & Whitehead, W. E. (2002) · Gastroenterology · doi:10.1053/gast.2002.37095 · Cited by 1,384 · cited 1×
“[7,8] It is a chronic functional gastrointestinal disorder characterized by abdominal pain and discomfort associated with altered bowel habits.”
BackgroundBiological, clinical, and ethical advances of placebo effects
Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61706-2 · Cited by 1,272
Self-citation
Research works printed but not linked: 1
- Vanner SJ Depew WT Paterson WG 2004 Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome and functional dyspepsia. Gut 53 666 72 · DOI · Paper page
Cited by
Items 401–500 of 897
Touwen, D. P., & Engberts, D. P. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.03.005 · Cited by 10
Attitudes on Mind Over Matter: Physician Views on the Role of Placebo in Psychogenic Disorders
Rommelfanger, K. S. (2013) · AJOB Neuroscience · doi:10.1080/21507740.2013.796327 · Cited by 10
“However, a recent study has demonstrated that placebo effects are maintained even when patients are aware that they are being given an “inert” substance (Kaptchuk et al. 2010).”
BackgroundBroelz, E. K., Wolf, S., Schneeweiß, P., Niess, A. M., Enck, P., & Weimer, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0198388 · Cited by 10
Prousky, J. E. (2018) · Journal of Evidence-Based Integrative Medicine · doi:10.1177/2515690x18794379 · Cited by 18
Placebos in the era of open‐label trials: An update for clinicians
Sagy, I., Abres, J., Winnick, A. A., & Jotkowitz, A. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13038 · Cited by 13
“For instance, the placebo response in the irritable bowel syndrome trial (59%) was substantially higher than reported placebo responses of 30%‐40% in other double‐blind irritable bowel syndrome trials.(77,85) It was hypothesized by the authors that while patients in double‐blind trials understand they have only a 50%…”
ResultOpen- and Closed-Label Placebo and Nocebo Suggestions About a Sham Transdermal Patch
Meeuwis, S. H., van Middendorp, H., Lavrijsen, A. P. M., Veldhuijzen, D. S., & Evers, A. W. M. (2020) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000862 · Cited by 12
“In previous studies, effects had always been measured over a longer period (29,47).”
BackgroundWritten expressive disclosure in adults with irritable bowel syndrome: A randomized controlled trial
Laird, K. T., & Stanton, A. L. (2021) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2021.101374 · Cited by 12
Lee, S., Choi, D.-H., Hong, M., Lee, I., & Chae, Y. (2022) · Journal of Integrative and Complementary Medicine · doi:10.1089/jicm.2021.0177 · Cited by 9
Self-Organizing Biopsychosocial Dynamics and the Patient-Healer Relationship
Pincus, D. (2012) · Forschende Komplementärmedizin / Research in Complementary Medicine · doi:10.1159/000335186 · Cited by 12
“For example, a recent outcome trial for irritable bowel syndrome [7] demonstrated that placebo pills produced significant improvements even when patients were informed that the pills they were taking were inert and the pill bottles were labeled “Placebo.”
BackgroundDeceit and transparency in placebo research.
Justman, S. (2013) · Europe PMC (PubMed Central) · Cited by 10
Estores, I. M., & Frye, J. (2015) · Critical Care Nursing Clinics of North America · doi:10.1016/j.cnc.2015.05.002 · Cited by 15
Placebo, usual care and wait-list interventions for all mental health disorders
Faltinsen, E., Todorovac, A., Hróbjartsson, A., Gluud, C., Kongerslev, M. T., Simonsen, E., & Storebø, O. J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.mr000050 · Cited by 9
Lay People’s Ethical Attitudes To Placebo Treatment: A Q-Methodology Study
Hammami, M. M., Hammami, S., Aboushaar, R., & Aljomah, A. S. (2019) · Patient Preference and Adherence · doi:10.2147/ppa.s216565 · Cited by 10
Patient-Physician Relationship in Irritable Bowel Syndrome: Review on Empathy and Stigma
Kuliavienė, I., Gelman, S., & Kupčinskas, J. (2024) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-5018 · Cited by 14
Ethical considerations in the treatment of multiple sclerosis fatigue
Nourbakhsh, B., Waubant, E. L., Evers, A. W. M., & Solomon, A. J. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103129 · Cited by 9
Rapport 21-09. La relation médecin-malade
Bontoux, D., Autret, A., Jaury, P., Laurent, B., Lévi, Y., & Olié, J. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.07.009 · Cited by 41
Helms, J. T., Mayhew, T. P., & Zimney, K. J. (2021) · Journal of Physical Therapy Education · doi:10.1097/jte.0000000000000191 · Cited by 11
Wagner, C., Gaab, J., & Hediger, K. (2023) · Journal of Pain · doi:10.1016/j.jpain.2023.01.004 · Cited by 11
Rosenzweig, E. L. (2016) · Perspectives on Psychological Science · doi:10.1177/1745691615621280 · Cited by 34
A comparative study with depressed patients on the acceptability of placebo use
Feffer, K., Lichtenberg, P., Becker, G., Bloch, Y., Netzer, R., & Nitzan, U. (2016) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2016.05.004 · Cited by 9
Treating Pain With Open-Label Placebos: A Qualitative Study With Post-Surgical Pain Patients
Bernstein, M. H., Fuchs, N., Rosenfield, M. N., Weiss, A. C., Blease, C., Locher, C., Magill, M., Rich, J. D., & Beaudoin, F. L. (2021) · Journal of Pain · doi:10.1016/j.jpain.2021.05.001 · Cited by 9
Stuhlreyer, J., Schwartz, M., Friedheim, T., Zöllner, C., & Klinger, R. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-059044 · Cited by 9
Milgrom, L. R. (2014) · European Journal of Integrative Medicine · doi:10.1016/j.eujim.2014.06.008 · Cited by 9
“[27] Kaptchuk TJ, Friedlander E, Kelley JM, Sanchez MN, Kokkatou E, Singer JP, et al.”
BackgroundEffet placebo et antidépresseurs : une revue de la littérature éclairée par la psychanalyse
Keller, P.-H., Giroux-Gonon, A., & Gonon, F. (2013) · L Évolution Psychiatrique · doi:10.1016/j.evopsy.2013.02.004 · Cited by 10
Informed consent and ECT: how much information should be provided?
Torrance, R. (2014) · Journal of Medical Ethics · doi:10.1136/medethics-2013-101885 · Cited by 9
Examining a Powerful Healing Effect through a Cultural Lens, and finding Meaning
Moerman, D. E. (2011) · Cited by 9
Nursing knowledge: hints from the placebo effect
Zanotti, R., & Chiffi, D. (2016) · Nursing Philosophy · doi:10.1111/nup.12140 · Cited by 9
The “placebo” paradox and the emotion paradox: Challenges to psychological explanation
Hutchinson, P. (2020) · Theory & Psychology · doi:10.1177/0959354320928139 · Cited by 10
“The conclusion—the actual conclusion—drawn from the trial (which, of course, did not include the fictional Miranda), based on 80 participants, was that knowing it is a placebo you are receiving does not necessarily nor reliably serve to negate the placebo response 7 (Kaptchuk et al., 2010).”
BackgroundInformed Consent, the Placebo Effect and Psychodynamic Psychotherapy
Blease, C. (2015) · Library of ethics and applied philosophy · doi:10.1007/978-3-319-17960-5_11 · Cited by 9
Editorial: Demystifying the Placebo Effect
Murray, E. J. (2020) · American Journal of Epidemiology · doi:10.1093/aje/kwaa162 · Cited by 10
Sezer, D., de Leeuw, M., Netzer, C. M., Dieterle, M., Meyer, A. H., Buergler, S., Locher, C., Ruppen, W., Gaab, J., & Schneider, T. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.687398 · Cited by 8
Karacaoglu, M., Meijer, S., Peerdeman, K. J., Dusseldorp, E., Jensen, K. B., Veldhuijzen, D. S., van Middendorp, H., & Evers, A. W. M. (2023) · Clinical Journal of Pain · doi:10.1097/ajp.0000000000001112 · Cited by 11
Schaefer, M., & Enge, S. (2024) · Scientific Reports · doi:10.1038/s41598-024-56600-6 · Cited by 9
“Then all participants were informed about the placebo effect as described previously 38 .”
BackgroundClark, A. (2024) · Entropy · doi:10.3390/e26080677 · Cited by 11
“In an earlier study, an honest placebo was administered to 80 patients suffering from Irritable Bowel Syndrome (IBS), resulting in clinically significant improvements in 59% (against 35% in a control group) [17].”
MethodReduction in caffeine withdrawal after open-label decaffeinated coffee
Mills, L., Lee, J. C., Boakes, R. A., & Colagiuri, B. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811221147152 · Cited by 7
“…and/or written suggestions by researchers that the placebo they were about to be given would somehow improve their symptoms (Carvalho et al., 2016; Kaptchuk et al., 2010; Kelley et al., 2012; Locher et al., 2017; Sandler & Bodfish, 2008; Zhou et al., 2018) (e.g. from Locher et al. (2017): ‘it is…”
BackgroundInfluentialEffects of (non)deceptive placebos on reported sleep quality and food cue reactivity
Potthoff, J., & Schienle, A. (2023) · Journal of Sleep Research · doi:10.1111/jsr.13947 · Cited by 7
“The OLP group leaflet was based on established recommendations for OLP administration (Kaptchuk et al., 2010) informing participants: (1) that placebos can have beneficial effects on various symptoms; (2) that the body can respond automatically to the placebo; and (3) that an optimistic attitude…”
MethodAulenkamp, J., Icenhour, A., & Elsenbruch, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1270189 · Cited by 11
Using Participant Choice to Enhance Memory Performance
Weger, U., & Loughnan, S. (2014) · Applied Cognitive Psychology · doi:10.1002/acp.3088 · Cited by 7
Harnessing the placebo effect: a promising method for curbing the opioid crisis?
Bernstein, M. H., Magill, M., Beaudoin, F. L., Becker, S. J., & Rich, J. D. (2018) · Addiction · doi:10.1111/add.14385 · Cited by 8
Describing Placebo Phenomena in Medicine: A Linguistic Approach
Sussex, R. (2018) · International review of neurobiology · doi:10.1016/bs.irn.2018.07.032 · Cited by 10
Pan, Y., Meister, R., Löwe, B., Winkelmann, A., Kaptchuk, T. J., Bühling, K. J., & Nestoriuc, Y. (2019) · Trials · doi:10.1186/s13063-019-3575-1 · Cited by 8
“The first randomized-controlled OLP trial demonstrated a significant improvement of irritable bowel syndrome after 3 weeks of placebo intake over an untreated control group with 60% (vs 35%) reporting adequate relief [30].”
BackgroundSelf-citationHruschak, V., Flowers, K. M., Patton, M. E., Merchantz, V., Schwartz, E., Edwards, R. R., Kaptchuk, T. J., Kang, J. D., Dossett, M. L., & Schreiber, K. L. (2022) · International Journal of Behavioral Medicine · doi:10.1007/s12529-022-10114-5 · Cited by 11
Self-citationSchienle, A., Kogler, W., & Wabnegger, A. (2023) · Scientific Reports · doi:10.1038/s41598-023-39806-y · Cited by 10
Häuser, W., Bartram-Wunn, E., Bartram, C., & Tölle, T. R. (2011) · Der Schmerz · doi:10.1007/s00482-011-1106-4 · Cited by 11
Clinical Use of Placebos: Still the Physician's Prerogative?
Barnhill, A. (2012) · The Hastings Center Report · doi:10.1002/hast.33 · Cited by 8
Controlling Placebo Response in Drug Development: Lessons Learned from Psychopharmacology
Potter, W. Z., Mallinckrodt, C. H., & Detke, M. J. (2014) · Pharmaceutical Medicine · doi:10.1007/s40290-014-0052-8 · Cited by 8
“those who were on no treatment [71].”
Nocebo and Informed Consent in the Internet Era
Meynen, G., Swaab, D. F., & Widdershoven, G. A. M. (2012) · The American Journal of Bioethics · doi:10.1080/15265161.2011.652801 · Cited by 8
Research on placebo analgesia is relevant to clinical practice
Gay, C. W., & Bishop, M. D. (2014) · Chiropractic & Manual Therapies · doi:10.1186/2045-709x-22-6 · Cited by 12
“One study administered open labeled placebos with patient education that described an active biological pathway for symptom improvement [26].”
BackgroundShould placebo be used routinely for chronic pain in older people?
Savvas, S. M., Zelencich, L. M., & Gibson, S. J. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.09.006 · Cited by 9
“Irritable bowel syndrome patients also have shown clinical improvement after being administered an open label placebo and told they were receiving a placebo and that placebos have been shown to improve symptoms [87].”
BackgroundMiller, F. G. (2018) · Perspectives in biology and medicine · doi:10.1353/pbm.2018.0046 · Cited by 8
Self-citationBishop, F. L., Greville-Harris, M., Bostock, J., Din, A., Graham, C. A., Lewith, G. T., Liossi, C., O’Riordan, T., White, P., & Yardley, L. (2019) · Journal of Medical Internet Research · doi:10.2196/jmir.9955 · Cited by 8
“PoP could be adapted to improve patients’ understanding of open-label placebo interventions [35,55] and/or to educate patients about placebo effects and mind-body interactions more broadly.”
Lembo, A. J., Covington, P. S., Dove, L. S., & Andrae, D. A. (2020) · Neurogastroenterology & Motility · doi:10.1111/nmo.13774 · Cited by 7
Self-citationA systematic review and meta analysis of open label placebo effects in chronic musculoskeletal pain
Borg, F., Gedin, F., Franzén, E., & Grooten, W. J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-09415-y · Cited by 8
“This finding could be noteworthy as previous studies 13,25–27 have shown that OLP is effective in individuals with more diffuse, widespread pain syndromes, while those with knee pain tend to perceive their pain as specific and localized.”
Benson, S., Theysohn, N., Kleine‐Borgmann, J., Rebernik, L., Icenhour, A., & Elsenbruch, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.824468 · Cited by 8
Placebos in pediatrics: A cross-sectional survey investigating physicians' perspectives
Faria, V., Talbert, C., Goturi, N., Borsook, D., Lebel, A., Kaptchuk, T. J., Kirsch, I., Kelley, J. M., & Moulton, E. A. (2023) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2023.111421 · Cited by 9
Self-citationBerna, C., Anne, F.-B., Adelaïde, B., Gross, N., Gonthier, A., Gerhard-Donnet, H., Taffé, P., & Hügli, O. (2023) · Psychosomatic Medicine · doi:10.1097/psy.0000000000001246 · Cited by 7
“Indeed, suggestions are a verbal part of communication, yet nonverbal aspects are important contributors to nonspecific treatment effects (12).”
BackgroundStumpp, L., Jauch, M., Sezer, D., Gaab, J., & Greifeneder, R. (2023) · Scientific Reports · doi:10.1038/s41598-023-42547-7 · Cited by 5
“…Material) presented by the experimenter in their own words, focusing on three important discussion points put forward by Kaptchuk et al. 34 : (1) previous research has found a powerful placebo effect, (2) the body can react automatically to taking a pill due to learning mechanisms, and…”
Krockow, E. M., Emerson, T. E., Youssef, E., Scott, S., & Tromans, S. J. (2023) · BMC Medicine · doi:10.1186/s12916-023-03074-4 · Cited by 9
“Some clinical trials used the term “sugar pill” as a synonymous term for “placebo” in patient communications [30, 31].”
MethodMethotrexate Intolerance in Juvenile Idiopathic Arthritis: Definition, Risks, and Management
Wibrand, C., Kyvsgaard, N., Herlin, T., & Glerup, M. B. (2024) · Pediatric Drugs · doi:10.1007/s40272-024-00643-9 · Cited by 7
“It should be noted, however, that this exact phenomenon has been demonstrated in other diseases [83–85].”
ResultWright-Hughes, A. M., Ford, A. C., Alderson, S. L., Ow, P. L., Ridd, M. J., Foy, R., Bishop, F. L., Chaddock, M., Cook, H., Cooper, D., et al. (2024) · Health Technology Assessment · doi:10.3310/bfcr7986 · Cited by 13
Skyt, I., & Vase, L. (2016) · Tidsskrift for Forskning i Sygdom og Samfund · doi:10.7146/tfss.v12i23.22895 · Cited by 7
Weimer, K., Horing, B., Muth, E. R., Scisco, J. L., Klosterhalfen, S., & Enck, P. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.022 · Cited by 7
Perspectives on Placebo: The Psychology of Neurofeedback
Thornton, K. E. (2018) · NeuroRegulation · doi:10.15540/nr.5.4.137 · Cited by 10
“The placebo group had a 50% pain reduction in 36% of the patients” (WRF, n.d.) Kaptchuk et al. (2010) studied two groups of irritable bowel syndrome (IBS) patients.”
BackgroundInfluentialCan the Open Label Placebo Rationale Be Optimized?
Heiss, U., Rosenfield, M. N., & Bernstein, M. H. (2021) · Frontiers in Pain Research · doi:10.3389/fpain.2021.734882 · Cited by 7
Zunhammer, M., Goltz, G., Schweifel, M., Stuck, B. A., & Bingel, U. (2022) · Clinical and Translational Science · doi:10.1111/cts.13397 · Cited by 7
The ethics of placebo treatments in clinical practice: a reply to Glackin
Barnhill, A., & Miller, F. G. (2015) · Journal of Medical Ethics · doi:10.1136/medethics-2014-102651 · Cited by 7
Self-citationKradin, R. L. (2011) · Perspectives in biology and medicine · doi:10.1353/pbm.2011.0046 · Cited by 8
Zaveri, H., Surve, A., Cottam, D. R., Medlin, W., Richards, C., Cottam, A., & Cottam, S. (2018) · Obesity Surgery · doi:10.1007/s11695-018-3369-7 · Cited by 7
Goo, S. J., Frangos, E., Richards, E. A., Čeko, M., Justement, B. L., Korb, P., Walitt, B. T., Colloca, L., & Bushnell, M. C. (2019) · Pain Medicine · doi:10.1093/pm/pnz081 · Cited by 8
Maximizing placebo response in neurological clinical practice
Mariani, L., & Corvol, J. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.04.003 · Cited by 9
Understanding the Placebo and Nocebo Effects in Patients With Irritable Bowel Syndrome.
Lembo, A. J. (2020) · PubMed Central · Cited by 7
Self-citationElectroconvulsive therapy: the importance of informed consent and ‘placebo literacy’
Blease, C. (2012) · Journal of Medical Ethics · doi:10.1136/medethics-2012-101201 · Cited by 7
Li, J., Liu, C., Zhang, N., Yan, C.-Q., Tu, J., Wang, Y., Qi, Y., Liu, J., & Wang, X. (2020) · Trials · doi:10.1186/s13063-020-04908-9 · Cited by 9
Annoni, M. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2013.346 · Cited by 7
“To test this hypothesis, in the third study presented by Kaptchuk, 80 volunteers with IBS were randomised to receive either no-treatment or a placebo pill twice a day [19].”
MethodTaylor, J. J., Szigeti, B., Silverberg, N. D., Ahmadzad-Asl, M., Kare, M. R., Webler, R. D., Orsini, D. K., Rosenblat, J. D., Bschor, T., Baethge, C., et al. (2026) · The Lancet Psychiatry · doi:10.1016/s2215-0366(26)00018-0 · Cited by 7
Efficacy of open-label placebos for premenstrual syndrome: a randomised controlled trial
Nascimento, A. F., Gaab, J., Degen, B., Rytz, M., Holder, A., Sezer, D., Buergler, S., Meyer, A. H., Kirsch, I., Kossowsky, J., et al. (2025) · BMJ Evidence-Based Medicine · doi:10.1136/bmjebm-2024-112875 · Cited by 9
“of the OLP+ group was in line with previous studies 23 31 32 and included an explanation about placebo effects and how placebos may decrease PMS symptoms.”
Self-citationMeasuring the placebo effect in carpal tunnel syndrome
Faig‐Martí, J., & Martínez‐Catasús, A. (2020) · Journal of Orthopaedics and Traumatology · doi:10.1186/s10195-019-0540-4 · Cited by 7
Schmidt, K., Kleine‐Borgmann, J., Holle, D., Gaul, C., & Bingel, U. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-045969 · Cited by 6
What you don't know can help you: An activating placebo effect in spider phobia
Siegel, P. F., & Peterson, B. S. (2021) · Behaviour Research and Therapy · doi:10.1016/j.brat.2021.103994 · Cited by 6
Rathschlag, M., & Klatt, S. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.658275 · Cited by 6
Can observational learning reinforce open-label placebo hypoalgesia?
Brączyk, J., & Bąbel, P. (2024) · Pain · doi:10.1097/j.pain.0000000000003161 · Cited by 8
“Moreover, modified instructions from Kaptchuk et al. 29 were implemented to familiarize the participants with the placebo effect and its mechanisms.”
BackgroundMethodRethinking Strategies to Screen for Celiac Disease
Baker, S. S. (2014) · PEDIATRICS · doi:10.1542/peds.2013-3631 · Cited by 6
A new perspective on “the placebo effect”: Untangling the entanglement
Manek, N. J., & Tiller, W. A. (2011) · Medical Hypotheses · doi:10.1016/j.mehy.2011.06.047 · Cited by 6
“The placebo effect has also been evaluated as a clinical treatment in itself when administered in a non-concealment fashion [5].”
BackgroundAn Integrative Medicine Approach to Asthma: Who Responds?
Kligler, B., McKee, M. D., Sackett, E., Levenson, H., Kenney, J., & Karasz, A. (2012) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2011.0540 · Cited by 6
Vase, L., Skyt, I., Petersen, G. L., & Price, D. D. (2014) · Zeitschrift für Psychologie · doi:10.1027/2151-2604/a000181 · Cited by 11
de Jong, V., & Raz, A. (2011) · Cited by 9
Placebo hypoalgesic effects in pain: Potential applications in dental and orofacial pain management
Blasini, M., Movsas, S., & Colloca, L. (2018) · Seminars in Orthodontics · doi:10.1053/j.sodo.2018.04.001 · Cited by 6
Wolter, T., & Kleinmann, B. (2018) · PLoS ONE · doi:10.1371/journal.pone.0206968 · Cited by 6
Druart, L., Longsworth, S. G., Rolland, C., Dolgopoloff, M., Terrisse, H., Bosson, J., & Pinsault, N. (2020) · Medicines · doi:10.3390/medicines7010003 · Cited by 8
“This study compared an open-label placebo (OLP) to a no treatment arm with patients suffering from irritable bowel syndrome (IBS) [27].”
BackgroundPlacebo, nocebo: Believing in the field of medicine
Meißner, K. (2022) · Frontiers in Pain Research · doi:10.3389/fpain.2022.972169 · Cited by 8
The Difficulties in Developing and Implementing Fibromyalgia Guidelines
Reed, M., & Herrm, M. (2012) · InTech eBooks · doi:10.5772/36495 · Cited by 8
Enck, P., Weimer, K., & Klosterhalfen, S. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397928-5.00016-7 · Cited by 6
The placebo puzzle: examining the discordant space between biomedical science and illness/healing
Pohlman, S., Cibulka, N. J., Palmer, J. L., Lorenz, R. A., & SmithBattle, L. (2012) · Nursing Inquiry · doi:10.1111/j.1440-1800.2012.00592.x · Cited by 7
The Total Food Effect: Exploring Placebo Analogies in Diet and Food Culture
Harris, C. S., & Johns, T. (2011) · Cited by 11
Hanaway, P. J. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1793-8.00040-6 · Cited by 6
The Use of Placebos in Clinical Trials and Clinical Practice
Kirsch, I. (2011) · The Canadian Journal of Psychiatry · doi:10.1177/070674371105600401 · Cited by 6
Self-citationEnthusiastic claims for open-label placebo pills ignore the evidence
Amorim, A. B., Machado, G. C., & Maher, C. G. (2020) · Pain · doi:10.1097/j.pain.0000000000001803 · Cited by 6
“A few small clinical trials have reported that open-label placebos can produce therapeutic benefits3 for a range of health conditions such as irritable bowel syndrome,4 allergic rhinitis,8 depression,5 and chronic low back pain.1 Kleine-Borgmann et al.6 recently published an open-label placebo trial in patients with c…”
BackgroundInfluentialPreserving the placebo effect after disclosure: A new perspective on non‐deceptive placebos
Andani, M. E., Barbiani, D., Bonetto, M., Menegaldo, R., Villa‐Sánchez, B., & Fiorio, M. (2024) · British Journal of Psychology · doi:10.1111/bjop.12696 · Cited by 7
Wessels, J., Klinger, R., Benson, S., Brenner, T., Elsenbruch, S., & Aulenkamp, J. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1396562 · Cited by 7
“Placebo treatments without deception, known as open-label placebo ( “ OLP ” ), meaning patients know and agree that they are receiving a placebo, can also produce positive treatment effects (26 – 29).”
BackgroundMethodFlávio‐Reis, V. H. P., Pessoa‐Gonçalves, Y. M., Diaz, C. A. V., Lamoglia, A. S. A., Desidério, C. S., & Oliveira, C. J. F. (2025) · Pain Management · doi:10.1080/17581869.2025.2467025 · Cited by 5
Metadata
- Authors
- Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., Kowalczykowski, M., Miller, F. G., Kirsch, I., & Lembo, A. J.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- National Institutes of Health (US)
- University of Hull (GB)
- Corresponding author
- Kaptchuk, Ted J.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-12-22
- Volume
- 5
- Issue
- 12
- Pages
- e15591
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3008733
- OpenAlex
- W2105330971
- Semantic Scholar
- 3d8aac4fba0e556c2d0898ad83cd3df11576e90c
- Cited by
- 900
- References
- 43
- Citations by year
- 2026: 28 · 2025: 44 · 2024: 48 · 2023: 56 · 2022: 55 · 2021: 67 · 2020: 72 · 2019: 55 · 2018: 97 · 2017: 48 · 2016: 55 · 2015: 55 · 2014: 65 · 2013: 48 · 2012: 58
- FWCI
- 29.43
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, public-domain)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- U.S. Department of Health and Human Services
- Bernard Osher Foundation
- National Institutes of Health (5r01at000402-04)
- Japan Society for the Promotion of Science (13J11021)
- National Center for Complementary and Alternative Medicine
- National Center for Complementary and Integrative Health (R01AT004662, K24AT004095, R01 AT00402-01)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Complementary and alternative medicine › Acupuncture Treatment Research Studies
- Keywords
- irritable bowel syndrome, placebo effect, open-label placebo, symptom severity, quality of life, patient-provider interaction, informed consent
- MeSH terms
- Adult, Female, Humans, Deception, Male, Middle Aged, Placebos, Time Factors, Treatment Outcome, Patient Satisfaction, Irritable Bowel Syndrome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

